AIM ImmunoTech Inc. (AIM) is a publicly traded Healthcare sector company. As of October 23, 2026, AIM trades at $0.16 with a market cap of $6.78M and a P/E ratio of 1.08. AIM moved -3.17% today. Year to date, AIM is -87.34%; over the trailing twelve months it is -93.75%. Its 52-week range spans $0.06 to $20.33. Analyst consensus is buy with an average price target of $4.25. Rallies surfaces AIM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for AIM combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $0.16 |
| Market Cap | $6.78M |
| P/E Ratio | 1.08 |
| EPS | $0.17 |
| Dividend Yield | 0.00% |
| 52-Week High | $20.33 |
| 52-Week Low | $0.06 |
| Volume | 669.56K |
| Avg Volume | 0 |
| Revenue (TTM) | $95.00K |
| Net Income | $-14.27M |
| Gross Margin | 0.00% |
2 analysts cover AIM: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.25.